Cargando…

Corrigendum to “Formation of a cytoplasmic salt bridge network in the matrix state is a fundamental step in the transport mechanism of the mitochondrial ADP/ATP carrier” [Biochim. Biophys. Acta 1857 (2016) 14–22]

Detalles Bibliográficos
Autores principales:	King, Martin S., Kerr, Matthew, Crichton, Paul G., Springett, Roger, Kunji, Edmund R.S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Pub. Co 2016
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084680/ https://www.ncbi.nlm.nih.gov/pubmed/27705820 http://dx.doi.org/10.1016/j.bbabio.2016.09.013

Ejemplares similares

Formation of a cytoplasmic salt bridge network in the matrix state is a fundamental step in the transport mechanism of the mitochondrial ADP/ATP carrier
por: King, Martin S., et al.
Publicado: (2016)

Corrigendum to “Cyclical strain modulates metalloprotease and matrix gene expression in human tenocytes via activation of TGFβ” [Biochim. Biophys. Acta (2013) 2596–2607]
por: Jones, Eleanor R., et al.
Publicado: (2013)

Corrigendum to “Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2” [Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1864/6 2019 941-956]
por: Nikolaou, Aikaterini, et al.
Publicado: (2019)

Modelling the free energy profile of the mitochondrial ADP/ATP carrier
por: Springett, Roger, et al.
Publicado: (2017)

Human mitochondrial ADP/ATP carrier SLC25A4 operates with a ping‐pong kinetic mechanism
por: Cimadamore‐Werthein, Camila, et al.
Publicado: (2023)

The Molecular Mechanism of Transport by the Mitochondrial ADP/ATP Carrier
por: Ruprecht, Jonathan J., et al.
Publicado: (2019)

Structural changes in the transport cycle of the mitochondrial ADP/ATP carrier
por: Ruprecht, Jonathan J, et al.
Publicado: (2019)

The mitochondrial ADP/ATP carrier exists and functions as a monomer
por: Kunji, Edmund R.S., et al.
Publicado: (2020)

Cardiolipin dynamics and binding to conserved residues in the mitochondrial ADP/ATP carrier
por: Duncan, Anna L., et al.
Publicado: (2018)

Characterization of drug-induced human mitochondrial ADP/ATP carrier inhibition
por: Jaiquel Baron, Stephany, et al.
Publicado: (2021)

Mitochondrial ADP/ATP Carrier in Dodecylphosphocholine Binds Cardiolipins with Non-native Affinity
por: Dehez, François, et al.
Publicado: (2017)

Involvement of (Na(+) + K(+))-ATPase in binding and actions of palytoxin on human erythrocytes: Böttinger, H., Béress, L. and Habermann, E. (Buchheim-Institut Für Pharmakologie, Justus-Liebig-Universität Giessen, Frankfurter Strasse 107, D-6300 Giessen, F.R.G.) Biochim. biophys. Acta861, 165–176. (1986).
Publicado: (1987)

Corrigendum to: ‘‘Salbutamol inhibits ubiquitin-mediated survival motor neuron protein degradation in spinal muscular atrophy cells’’ [Biochem. Biophys. Rep. 4 (2015) 351–356]
por: Harahap, Nur Imma Fatimah, et al.
Publicado: (2015)

Corrigendum “Transcriptional modulation of pattern recognition receptors in chronic colitis in mice is accompanied with Th1 and Th17 response” [Biochem. Biophys. Rep. 12 (2017) 29–39]
por: Zheng, Bin, et al.
Publicado: (2018)

Calcium‐regulated mitochondrial ATP‐Mg/P(i) carriers evolved from a fusion of an EF‐hand regulatory domain with a mitochondrial ADP/ATP carrier‐like domain
por: Harborne, Steven P. D., et al.
Publicado: (2018)

Corrigendum to “Thiolated silicone oil: Synthesis, gelling and mucoadhesive properties” [Acta Biomater. 16 (2015) 169–177]
por: Partenhauser, Alexandra, et al.
Publicado: (2015)

ADPriboDB: The database of ADP-ribosylated proteins
por: Vivelo, Christina A., et al.
Publicado: (2017)

The molecular features of uncoupling protein 1 support a conventional mitochondrial carrier-like mechanism
por: Crichton, Paul G., et al.
Publicado: (2017)

Substrate binding in the mitochondrial ADP/ATP carrier is a step-wise process guiding the structural changes in the transport cycle
por: Mavridou, Vasiliki, et al.
Publicado: (2022)

Corrigendum to “Actin Alpha 2 (ACTA2) Downregulation Inhibits Neural Stem Cell Migration through Rho GTPase Activation”
por: Zhang, Ji, et al.
Publicado: (2020)

Analysis of Mono-ADP-Ribosylation Levels in Human Colorectal Cancer [Corrigendum]
Publicado: (2021)

A Single Cysteine Residue in the Translocation Pathway of the Mitosomal ADP/ATP Carrier from Cryptosporidium parvum Confers a Broad Nucleotide Specificity
por: King, Martin S., et al.
Publicado: (2020)

Calcium-induced conformational changes in the regulatory domain of the human mitochondrial ATP-Mg/Pi carrier
por: Harborne, Steven P.D., et al.
Publicado: (2015)

Calcium regulation of the human mitochondrial ATP-Mg/Pi carrier SLC25A24 uses a locking pin mechanism
por: Harborne, Steven P. D., et al.
Publicado: (2017)

Actas oficiales : y minutario de decretos del Congreso Extraordinario Constituyente de 1856-1857
Publicado: (1957)

Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients
por: Tonini, G, et al.
Publicado: (2005)

Corrigendum to “Myoinositol: The Bridge (PONTI) to Reach a Healthy Pregnancy”
por: Cavalli, Pietro, et al.
Publicado: (2018)

ATP dependent NS3 helicase interaction with RNA: insights from molecular simulations
por: Pérez-Villa, Andrea, et al.
Publicado: (2016)

Nonsense-mediated mRNA decay factor Upf2 exists in both the nucleoplasm and the cytoplasm
por: Tatsuno, Takanori, et al.
Publicado: (2017)

Evolutionary Genetics of Cytoplasmic Incompatibility Genes cifA and cifB in Prophage WO of Wolbachia
Publicado: (2019)

Actas
por: Cedrón, José Antonio
Publicado: (1986)

Actas /
Publicado: (1986)

Actas.
Publicado: (1985)

Actas /
Publicado: (1972)

Actas /
Publicado: (1995)

Actas
Publicado: (1998)

Actas
Publicado: (1988)

Novel activity of eukaryotic translocase, eEF2: dissociation of the 80S ribosome into subunits with ATP but not with GTP
por: Demeshkina, Natalia, et al.
Publicado: (2007)

MSTO1 is a cytoplasmic pro‐mitochondrial fusion protein, whose mutation induces myopathy and ataxia in humans
por: Gal, Aniko, et al.
Publicado: (2023)

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
por: Drew, Yvette, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c0hu0mpaorll6bc811usuo2vqs